Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...